Quantifying the impact of survivor treatment bias in observational studies
Austin PC, Mamdani MM, van Walraven C, Tu JV. J Eval Clin Pract. 2006; 12(6):601-12.
Publications
Mental health-related drug utilization among older adults: prevalence, trends, and costs
Mamdani M, Rapoport M, Shulman KI, Herrmann N, Rochon PA. Am J Geriatr Psychiatry. 2005; 13(10):892-900.
Atypical antipsychotics and parkinsonism
Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, Normand SL, Mamdani M, Lee PE, Li P, Bronskill SE, Marras C, Gurwitz JH. Arch Intern Med. 2005; 165(16):1882-8.
Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada
Austin PC, Mamdani MM. Circulation. 2005; 112(9):1296-300. Epub 2005 Aug 22.
Antipsychotic use in the elderly: shifting trends and increasing costs
Rapoport M, Mamdani M, Shulman KI, Herrmann N, Rochon PA. Int J Geriatr Psychiatry. 2005; 20(8):749-53.
Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario’s Elderly
Croup hospitalizations in Ontario: a 14-year time-series analysis
Segal AO, Crighton EJ, Moineddin R, Mamdani M, Upshur RE. Pediatrics. 2005; 116(1):51-5.
Antipsychotic medications and drug-induced movement disorders other than Parkinsonism: a population-based cohort study in older adults
Lee PE, Sykora K, Gill SS, Mamdani M, Marras C, Anderson G, Shulman KI, Stukel T, Normand SL, Rochon PA. J Am Geriatr Soc. 2005; 53(8):1374-9.
The use of the propensity score for estimating treatment effects: administrative versus clinical data
Austin PC, Mamdani MM, Stukel TA, Anderson GM, Tu JV. Stat Med. 2005; 24(10):1563-78.
Are rates of gastrointestinal bleeding higher following the introduction of COX-2 inhibitors?
Mamdami M. Expert Opin Drug Saf. 2005; 4(3):591-8.